{"analyses":[{"ciLowerLimit":"0.793","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.289","estimateComment":"Tremelimumab is the numerator and Placebo the denominator","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.926","pValueComment":"Estimated using the methods of Klein et al. 2007 and Whitehead and Whitehead 1991, stratified by EORTC status and line of therapy.","paramType":"Hazard Ratio (HR)","paramValue":"1.011","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.4","upperLimit":"21.8","value":"17.4"},{"groupId":"OG001","lowerLimit":"12.7","upperLimit":"24.5","value":"18.2"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"382"},{"groupId":"OG001","value":"189"}],"units":"Participants"}],"description":"The percentage of patients still alive at 18 months","dispersionType":"95% Confidence Interval","groups":[{"description":"Tremelimumab 10mg/kg","id":"OG000","title":"TREMELIMUMAB"},{"description":"Placebo.","id":"OG001","title":"PLACEBO"}],"paramType":"NUMBER","populationDescription":"ITT population","reportingStatus":"POSTED","timeFrame":"18 months","title":"OS Rate at 18 Months by Treatment Arm","type":"SECONDARY","typeUnitsAnalyzed":"Participants","unitOfMeasure":"Percentage of Participants"}